First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors
ESMO Open(2023)
Abstract
AK109 showed manageable safety profile and promising antitumor activity, supporting further clinical development in a large population.
MoreTranslated text
Key words
AK109,anti-VEGFR2 antibody,phase I study,solid tumors
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined